How should I budget for peptide mapping across a twelve-month semaglutide course?

The specifics, since they change the answer: peptide mapping · semaglutide.

I would like to define my thresholds before I have a result, for obvious reasons.

I want a plan with explicit stopping rules, not just steps.

What is the minimum version of this that is still defensible?

Twelve months is 52 weeks, so the budget is set by lot turnover, not by the price of peptide mapping. Take one lot a quarter as the low case: 4 lots a year, so a test-every-lot policy is 4 assays and a test-every-third-lot policy is 2 once you round up. Take one lot a month as the high case: 12 lots, and the same two policies are 12 assays and 4. The spread between the cheapest and the dearest defensible policy is therefore about a factor of six across the same 52 weeks. Choose the policy before the first result. One chosen after a disappointing figure is a reaction to that figure, and it will not survive the second one. Then spend it where it changes a decision: over a year, one content assay on each new lot tells you more than four purity figures on the same lot, because purity and content are independent and only one of them changes your arithmetic.

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Assume segregation is possible, and design your sampling to catch it if it exists.

In practice, most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Specifically, if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

If testing multiple vials, state how many you tested and why you chose those vials.